KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Operating Expenses (2018 - 2025)

Historic Operating Expenses for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $43.7 million.

  • Aurinia Pharmaceuticals' Operating Expenses fell 2195.53% to $43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $195.8 million, marking a year-over-year decrease of 2262.41%. This contributed to the annual value of $239.8 million for FY2024, which is 1024.83% down from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Operating Expenses of $43.7 million as of Q3 2025, which was down 2195.53% from $49.9 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Operating Expenses' 5-year high stood at $74.8 million during Q4 2023, with a 5-year trough of $40.6 million in Q1 2025.
  • For the 5-year period, Aurinia Pharmaceuticals' Operating Expenses averaged around $58.6 million, with its median value being $58.7 million (2024).
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Operating Expenses surged by 36554.78% in 2021, and later crashed by 3609.1% in 2025.
  • Aurinia Pharmaceuticals' Operating Expenses (Quarter) stood at $56.1 million in 2021, then increased by 0.76% to $56.5 million in 2022, then surged by 32.25% to $74.8 million in 2023, then dropped by 17.7% to $61.5 million in 2024, then dropped by 28.95% to $43.7 million in 2025.
  • Its Operating Expenses was $43.7 million in Q3 2025, compared to $49.9 million in Q2 2025 and $40.6 million in Q1 2025.